CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased ...
CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, ...
Only a few years ago the benefits of lateral flow diagnostic tests weren’t widely understood outside of scientific circles. The reason most people came into contact with the technology was through the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results